Quick jump to page content
Main Navigation
Main Content
Sidebar
Register
Login
Toggle navigation
Home
About
About the Journal
Submissions
Editorial Team
Privacy Statement
Contact
Current
Archives
Submission
Search
Search
Search articles for
Advanced filters
Published After
2017
2018
2019
2020
2021
2022
2023
2024
January
February
March
April
May
June
July
August
September
October
November
December
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Published Before
2017
2018
2019
2020
2021
2022
2023
2024
January
February
March
April
May
June
July
August
September
October
November
December
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
By Author
Search Results
Omalizumab Retreatment of Patients swith Chronic Idopathic Urticaria/Spontaneous Urticaria (CIU/CSU) Following Return of Symptoms: Primary Results of the OPTIMA Study
Gordon Sussman, Jacques Hebert, Wayne Gulliver, Charles Lynde, William H Yang, Olivier Chambenoit, Antonio Vieira, Frederica De Takacsy, Lenka Rihakova
Page s127
Poster PDF
Design and rational of the OPTIMA Study: Retreatment or Step-Up Therapy with Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU)
Gordon Sussman, Jacques Hebert, Wayne Gulliver, Charles Lynde, William H Yang, Olivier Chambenoit, Gretty Deutsch, Frederica DeTakacsy, Lenka Rihakova
Page s125
Poster PDF
Efficacy and Safety of Omalizumab in Japanese and Korean Patients with Chronic Idopathic/Spontaneous Urticaria (CIU/CSU: Results from the Phase 3 POLARIS Study
Michihiro Hide, Hae-Sim Park, Atsuyuki Igarashi, Young-Min Ye, Tae-Bum Kim, Akiko Yagami
Page s126
Poster PDF
Omalizumab Retreatment of Patients with Chronic Idiopathic Urticaria/Spontaneous Urticaria (CIU/CS) Following Return of Symptoms: Primary Results of the Optima Study
Gordon Sussman, Jacques Hebert, Wayne Gulliver, Charles Lynde, William H Yang, Olivier Chambenoit, Antonio Vieira, Frederica DeTakaosy, Lenka Rihakova
Page S54
Poster PDF
Comparison of Study Designs for Primary Phase III Trials for Omalizumab Versus Dupilumab for Patients With Chronic Spontaneous Urticaria
Andrew Alexis, Kyle Anders, Arpamas Seetasith, Michael Holden
Page s333
PDF
Comparison of Study Designs for Primary Phase III Trials for Omalizumab Versus Dupilumab for Patients With Chronic Spontaneous Urticaria
Andrew Alexis, Kyle Anders, Arpamas Seetasith, Michael Holden
Page s299
PDF
Omalizumab Improves Angioedema-Related Quality of Life Impariment in Patients with Chronic Idiopathic/Chronic Spontaneous Urticaria: Results from the X-Act Study
Karsten Weller, Petra Staubach, Martin Metz, Nadine Chapman-Rothe, Christian Sieder, Matthias Brautigam, Marcus Maurer
Page S53
Poster PDF
Design and Rationale of the OPTIMA Study: Retreatment or Step-Up Therapy with Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU)
Gordon Sussman, Jacques Hebert, Wayne Gulliver, Charles Lynde, William H Lang, Olivier Chambenoit, Gretty Deutsch, Frederica DeTakaosy, Lenka Rihakova
Page S51
Poster PDF
Omalizumab Dose Step-Up and Treatment Response in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU): Results from the OPTIMA Study
Wayne Gulliver, Gordon Sussman, Jacques Hebert, Charles W Lynde, Kim A Papp, William H Yang, Olivier Chambenoit, Antonio Viera, Frederica DeTakaosy, Lenka Rihakova
Page S52
Poster PDF
1 - 9 of 9 items
×
Modal Header